Clinical effects of human macrophage inflammatory protein-1 alpha MIP-1 (LD78) administration to humans: a phase I study in cancer patients and normal healthy volunteers with the genetically engineered variant, BB-10010

Author： Marshall E.   Howell A.H.   Powles R.   Hunter M.G.   Edwards M.   Wood L.M.   Czaplewski L.   Puttick R.   Warrington S.   Boyce M.   Testa N.   Dexter T.M.   Lord B.I.   Millar A.  

Publisher： Elsevier

ISSN： 0959-8049

Source： European Journal of Cancer, Vol.34, Iss.7, 1998-06, pp. : 1023-1029

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A phase I clinical and pharmacokinetic study of the multi-drug resistance protein-1 (MRP-1) inhibitor sulindac, in combination with epirubicin in patients with advanced cancer

By O’Connor R.   O’Leary M.   Ballot J.   Collins C.   Kinsella P.   Mager D.   Arnold R.   O’Driscoll L.   Larkin A.   Kennedy S.   Fennelly D.   Clynes M.   Crown J.  

Cancer Chemotherapy and Pharmacology, Vol. 59, Iss. 1, 2007-01 ,pp. : 79-87

Springer Publishing Company

Access to resources Recommend Favorite

A phase I combination chemotherapy study of biweekly paclitaxel and S-1 administration in patients with advanced gastric cancer

By Hokita Shuichi   Aikou Takashi   Miyazono Futoshi   Ishigami Sumiya   Aridome Kuniaki   Maenohara Shigeho   Saihara Tetsushi   Suenaga Kuniaki   Nomura Hidehiro   Maeda Satoshi   Takatori Hiroyuki   Arima Hideo   Uchikado Yasuto   Natsugoe Shoji   Takao Sonshin  

Cancer Chemotherapy and Pharmacology, Vol. 57, Iss. 6, 2006-06 ,pp. : 736-740

Springer Publishing Company

Access to resources Recommend Favorite

Macrophage inflammatory protein (MIP)1α and MIP1β differentially regulate release of inflammatory cytokines and generation of tumoricidal monocytes in malignancy

By Nath Anamika   Chattopadhya Sreya   Chattopadhyay Utpala   Sharma Nawal  

Cancer Immunology, Immunotherapy, Vol. 55, Iss. 12, 2006-12 ,pp. : 1534-1541

Springer Publishing Company

Access to resources Recommend Favorite

Phase I clinical and pharmacokinetic/pharmacogenetic study of a triplet regimen of S-1/irinotecan/oxaliplatin in patients with metastatic colorectal or gastric cancer

By Park Sook   Hong Yong   Lim Hyeong-Seok   Seong Moon-Woo   Kong Sun-Young   Kim Sun   Park Young-Iee   Jung Kyung  

Cancer Chemotherapy and Pharmacology, Vol. 72, Iss. 5, 2013-11 ,pp. : 953-964

Springer Publishing Company

Access to resources Recommend Favorite

Phase I clinical trial of peptide vaccination with URLC10 and VEGFR1 epitope peptides in patients with advanced gastric cancer

By                  

International Journal of Oncology, Vol. 44, Iss. 3, 2014-01 ,pp. : 662-668

Spandidos Publications

Access to resources Recommend Favorite